J. Duan

Lifeng Wang, Yong Fang, Haihua Yang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cetuximab combination with chemotherapy in advanced non-small cell lung cancer

J. Duan, Jun Zhao, T. An, 2009 .

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

Jie He, Bingding Huang, Shuhang Wang, 2019, Journal of Immunotherapy for Cancer.

DNA Damage Response Gene-Based Subtypes Associated With Clinical Outcomes in Early-Stage Lung Adenocarcinoma

Guoqiang Wang, S. Cai, J. Duan, 2022, Frontiers in Molecular Biosciences.

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer

F. Tan, Jie He, H. Bai, 2020, Thoracic cancer.

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

J. Duan, Zhijie Wang, Jie Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer

F. Tang, Zhaoli Chen, Shuhang Wang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

W. Feng, H. Pan, Xiaorong Dong, 2021, EClinicalMedicine.

肺癌骨转移诊疗专家共识（2014版）

Mengzhong Liu, Qinghua Zhou, Jun Liang, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

541例女性晚期非小细胞肺癌患者的预后因素分析

H. Bai, M. Zhuo, J. Duan, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Noninvasive cancer detection by extracting and integrating multi-modal data from whole-methylome sequencing of plasma cell-free DNA

F. Tan, Xi Li, Yuan Li, 2022, bioRxiv.

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

J. Duan, Jie Wang, Tianyu Wang, 2021, Thoracic cancer.

Malignant pleural effusion cell blocks are substitutes for tissue in EML4‐ALK rearrangement detection in patients with advanced non‐small‐cell lung cancer

Xianxin Li, X. Li, H. Bai, 2016, Cytopathology : official journal of the British Society for Clinical Cytology.

[The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis.].

H. Bai, J. Duan, Zhijie Wang, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Consensus for HER2 alterations testing in non-small-cell lung cancer

F. Hirsch, T. Mitsudomi, X. Wang, 2022, ESMO open.

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer

H. Bai, M. Zhuo, J. Duan, 2017, Oncotarget.

Correlation among Genetic Variations of c-MET in Chinese Patient with Non-Small Cell Lung Cancer

H. Bai, M. Zhuo, J. Duan, 2017 .

[Primary lung cancer with gastrointestinal metastasis: 2 case report and literature review].

M. Zhuo, J. Duan, Zhijie Wang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

H. Bai, J. Duan, Zhijie Wang, 2020, Journal of Cancer.

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer

Si Li, M. Xiao, Dong-sheng Chen, 2022, Cell proliferation.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer

X. Wang, Shuhang Wang, Y. Shao, 2020, EBioMedicine.

[Characteristics and treatment of bone metastases in 322 cases non-small cell lung cancer: a retrospective study].

Shuhang Wang, J. Duan, Zhijie Wang, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

P. Xing, Junling Li, Yan Wang, 2022, BMC Medicine.

A metagenome association study of gut microbiome revealed biomarkers for chemotherapy efficacy in locally advanced and advanced lung cancer

H. Bai, J. Duan, Zhijie Wang, 2020 .

Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis

H. Bai, Y. Chai, J. Duan, 2022, Thoracic cancer.

The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study

H. Bai, J. Duan, Zhijie Wang, 2020, Cancer management and research.

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer

F. Tang, Qingqing Li, C. Gay, 2022, Signal Transduction and Targeted Therapy.

Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer

H. Bai, J. Duan, Zhijie Wang, 2022, Thoracic cancer.

[Individualized treatment recommendations for lung cancer patients at different stages of treatment during the outbreak of 2019 novel coronavirus disease epidemic].

H. Bai, J. Duan, Z. Zhao, 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma

H. Bai, J. Duan, L. Cai, 2022, Journal of oncology.

Clinical features of patients with lung adenocarcinomas harboring BRAF V600E mutations.

Shuhang Wang, H. Bai, M. Zhuo, 2013 .

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

X. Yi, Xiao Chen, Y. Guan, 2022, Cancers.

Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis

Ning Li, H. Bai, J. Duan, 2019, Thoracic cancer.

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Shuhang Wang, Jian Zhu, H. Bai, 2012, Journal of Experimental & Clinical Cancer Research.

IMPACT: a web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers

S. Cai, J. Duan, Zhijie Wang, 2023, bioRxiv.

Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis

H. Bai, Guoqiang Wang, J. Duan, 2021, Journal of the National Cancer Center.

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

H. Bai, S. Cai, J. Duan, 2021, BMC Medicine.

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers

D. Carbone, Wei Zhao, G. Feng, 2021, Science Advances.

The Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-Analysis

Guoqiang Wang, J. Duan, Zhijie Wang, 2020 .

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma

H. Bai, Guoqiang Wang, S. Cai, 2020, Journal for ImmunoTherapy of Cancer.

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Jie He, Jianjun Zhang, Yanhua Tian, 2020, BMC Medicine.

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer

Xueda Hu, Zemin Zhang, Fan Zhang, 2020, Cancer Immunology, Immunotherapy.

Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.

Shuhang Wang, Junling Li, Yanhua Tian, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells

X. Xie, Shuhang Wang, Ruoyan Li, 2019, Clinical Cancer Research.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Jing Zhao, Guoqiang Wang, Jun Zhao, 2019, JAMA oncology.

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

T. Mok, Zemin Zhang, Shuhang Wang, 2018, Cancer research.

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Qinghua Zhou, H. Bai, M. Zhuo, 2013, PloS one.

Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas

Yan Wang, Hanxiao Chen, Tiantian Gu, 2021, Journal of the National Cancer Center.

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

Shuhang Wang, G. Zhu, H. Bai, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

Jun-ling Li, Yan Wang, X. Hao, 2019, Investigational New Drugs.

Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations

Zemin Zhang, Zhirong Shen, Xiaodong Wang, 2015, Proceedings of the National Academy of Sciences.

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

Shuhang Wang, H. Bai, J. Duan, 2020, Frontiers in Immunology.

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Shuhang Wang, Yanhua Tian, H. Bai, 2019, Cancer Immunology Research.

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies

H. Bai, J. Duan, Zhijie Wang, 2015, Thoracic cancer.

Complete response induced by anti–PD‐1‐based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report

J. Duan, Xin Wang, N. Bi, 2020, Journal of clinical pharmacy and therapeutics.

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations

Shuhang Wang, Zhirong Shen, H. Bai, 2015, Scientific Reports.

Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer.

Wei Zhao, Shuhang Wang, Zhirong Shen, 2019, Cancer letters.

Impact of PD‐L1, transforming growth factor‐β expression and tumor‐infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors

H. Bai, J. Duan, Yu Sun, 2018, Thoracic cancer.

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Shuhang Wang, H. Bai, J. Duan, 2012, Journal of experimental & clinical cancer research : CR.

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

Shuhang Wang, H. Bai, M. Zhuo, 2015, Journal of Hematology & Oncology.

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

H. Bai, M. Zhuo, J. Duan, 2015, Thoracic cancer.

In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy.

Zhengyi Zhao, Guoqiang Wang, J. Duan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

X. Wang, Shuhang Wang, Junling Li, 2020 .

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

H. Bai, J. Duan, Jun Zhao, 2016, Chinese journal of cancer.

Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non‐small cell lung cancer when treated with EGFR‐tyrosine kinase inhibitors

H. Bai, M. Zhuo, J. Duan, 2014, Thoracic cancer.

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

H. Bai, J. Duan, Zhijie Wang, 2023, Frontiers of Medicine.

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer

Shuhang Wang, Qinghua Zhou, H. Bai, 2013, PloS one.

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Shuhang Wang, Yilong Wu, H. Bai, 2012, Oncology.

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

X. Wang, Shuhang Wang, H. Bai, 2010, Clinical Cancer Research.

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

Shuhang Wang, S. Song, H. Bai, 2010, Lung cancer.

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment.

Ying Cheng, Yi-long Wu, Yuankai Shi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.

Shuhang Wang, Hanxiao Chen, H. Bai, 2017, Oncology letters.

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

R. Chen, Shuhang Wang, H. Bai, 2014, PloS one.

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI

Shuhang Wang, H. Bai, M. Zhuo, 2012, Thoracic cancer.

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

Qinghua Zhou, Li Mao, Jun Zhao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.

J. Yu, H. Bai, J. Duan, 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Analysis of BIM (BCL‐2 like 11 gene) deletion polymorphism in Chinese non‐small cell lung cancer patients

H. Bai, J. Duan, Jun Zhao, 2014, Thoracic cancer.

Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer

T. Mok, Ping Yang, H. Bai, 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

H. Bai, M. Zhuo, J. Duan, 2016, Oncotarget.

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Lai Wei, Shuhang Wang, Jian Zhu, 2012, Journal of experimental & clinical cancer research : CR.

Yibo Gao, F. Tan, Q. Xue, 2021, The Lancet. Oncology.

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

H. Bai, J. Duan, Jie Wang, 2023, Frontiers in Oncology.

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

Jingjing Liu, Ying Cheng, B. Han, 2021, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

H. Bai, Guoqiang Wang, J. Duan, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systematic investigations of COVID-19 in 283 cancer patients

Q. Wang, Y. Xu, J. Ren, 2020, medRxiv.

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

Hanxiao Chen, H. Bai, M. Zhuo, 2018, Thoracic cancer.

A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China

H. Bai, J. Duan, Zhijie Wang, 2010 .

High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy

H. Bai, J. Duan, Zhijie Wang, 2010 .

Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.

H. Bai, M. Zhuo, J. Duan, 2014, Molecular and clinical oncology.

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study

F. Tan, X. Hao, J. Duan, 2023, Frontiers in Oncology.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

J. Lee, Qing Wang, J. Zhao, 2019, JAMA oncology.

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

H. Bai, Y. Chai, J. Duan, 2022, Journal of clinical medicine.

Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling

Zhaoli Chen, Jie He, J. Gu, 2018, Clinical Cancer Research.

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Jie Tian, Yanhua Tian, Yang Du, 2020, Journal for ImmunoTherapy of Cancer.

Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer

Wei Zhao, Shuhang Wang, Hanxiao Chen, 2018, Clinical Cancer Research.

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.

Hanxiao Chen, H. Bai, Yahui Tian, 2022, Future oncology.

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Shuhang Wang, H. Bai, J. Duan, 2012, Journal of experimental & clinical cancer research : CR.

Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.

J. Duan, Yunfei Shi, Zhenhua Yang, 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

Shuhang Wang, Hanxiao Chen, M. Zhuo, 2020, Thoracic cancer.

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment

Yanhua Tian, H. Bai, J. Duan, 2023, Thoracic cancer.

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

X. Hao, J. Duan, Zhijie Wang, 2023, Therapeutic advances in medical oncology.

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama

H. Bai, J. Duan, Liangliang Cai, 2023, BMC Cancer.

铂类抗肿瘤药物相关肾损伤作用机制的研究进展

Feifei Yan, J. Duan, Jie Wang, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study

Li Yang, J. Duan, Jie Wang, 2021, Journal of thoracic disease.

A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression

H. Bai, J. Duan, Zhijie Wang, 2009 .

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Wenfeng Li, Baocheng Wang, J. Wang, 2023, Therapeutic advances in medical oncology.

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments

H. Bai, M. Zhuo, J. Duan, 2017, Thoracic cancer.

[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer].

Hanxiao Chen, M. Zhuo, J. Duan, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer].

Hanxiao Chen, M. Zhuo, J. Duan, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Circular RNA ZNF292 affects proliferation and apoptosis of hepatocellular carcinoma cells by regulating Wnt/β-catenin pathway.

J. Duan, J. Wang, H. Ding, 2020, European Review for Medical and Pharmacological Sciences.

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

W. Liang, Chuanhao Tang, Jin-liang Wang, 2023, Journal of the National Cancer Center.

Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC).

Yibo Gao, Fanshuang Zhang, Ziran Zhao, 2019, Journal of Clinical Oncology.

An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type.

X. Liu, H. Bai, J. Duan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

H. Bai, S. Song, M. Zhuo, 2011, Chinese Medical Journal.

Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

H. Bai, J. Duan, T. An, 2011, Journal of Clinical Oncology.

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC

J. Duan, Yiyi Huang, Y. Chau, 2023, International journal of molecular sciences.

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy

H. Bai, J. Duan, Zhijie Wang, 2023, Cell reports methods.

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity

J. Duan, Jiachen Xu, Xue Zhang, 2023, Cell reports. Medicine.

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

J. Duan, R. Wan, Jie Wang, 2024, Heliyon.

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer

W. Feng, Jialei Wang, Xiaolong Yan, 2023, Thoracic cancer.

Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines

H. Bai, J. Duan, Zhijie Wang, 2023, Journal of the National Cancer Center.

[The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer].

H. Bai, J. Duan, Jun Zhao, 2008, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

Evaluation of First-line and Salvage Therapies for Unresectable Malignant Mesothelioma: A Systematic Review and Network Meta-Analysis

J. Duan, Zhijie Wang, R. Wan, 2024, Critical Reviews in Oncology/Hematology.

Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy

J. Duan, Xue Zhang, R. Wan, 2024, Heliyon.

Screening for depression and anxiety in lung cancer patients: A real‐world study using GAD‐7 and HADS

Huixia Zhou, J. Duan, Hengqin Ren, 2024, Thoracic Cancer.

Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.

J. Duan, W. Fang, R. Wan, 2024, Med.

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

Zhirong Shen, J. Duan, Jun Zhao, 2023, Cell reports. Medicine.